Blog
RSS FeedPosted by Michael Wonder on 02 May 2023
Libtayo (cemiplimab) in combination with chemotherapy now approved in Canada for the first-line treatment of advanced non-small cell lung cancer
1 May 2023 - Approval marks second first-line indication in NSCLC and fifth indication for Libtayo in Canada. ...
Posted by Michael Wonder on 01 May 2023
Canada’s health minister denies interfering in agency’s efforts to lower drug costs
27 April 2023 - Health Minister Jean-Yves Duclos says he has not exercised any undue political pressure on the independent ...
Posted by Michael Wonder on 29 Apr 2023
Arcutis announces Canadian approval of Zoryve (roflumilast) cream 0.3% for treatment of plaque psoriasis in individuals 12 years and older
28 April 2023 - First Zoryve approval outside of the US marks key milestone for Arcutis. ...
Posted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 27 Apr 2023
CADTH formalises offering on real-world evidence through its scientific advice program
25 April 2023 - During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence ...
Posted by Michael Wonder on 24 Apr 2023
Health Canada approves new antibody drug to help prevent serious RSV in babies
22 April 2023 - Health Canada has approved a new antibody drug to help protect babies from serious illness caused ...
Posted by Michael Wonder on 20 Apr 2023
Rybrevant (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations
6 April 2023 - This CADTH recommendation is a step towards public access to Rybrevant as a targeted therapy for ...
Posted by Michael Wonder on 18 Apr 2023
Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with haemophilia B with inhibitors
17 April 2023 - New treatment option for Canadians living with rare and serious X-chromosome linked congenital bleeding disorder ...
Posted by Michael Wonder on 15 Apr 2023
Pfizer Canada initiates submission to Health Canada for its bivalent respiratory syncytial virus vaccine
14 April 2023 - Indications under review include prevention of respiratory syncytial virus in infants from birth through 6 months ...
Posted by Michael Wonder on 13 Apr 2023
Vertex announces Health Canada market authorisation for Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis ages 1 to <2 years
10 April 2023 - With this approval, approximately 30 children with two copies of the F508del mutation are eligible for ...
Posted by Michael Wonder on 04 Apr 2023
Koselugo approved in Canada for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas
3 April 2023 - First and only therapy approved to treat this rare and debilitating genetic condition. ...
Posted by Michael Wonder on 04 Apr 2023
Chiesi Global Rare Diseases announces approval of Ferriprox MR deferiprone extended release tablets in Canada
31 March 2023 - New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassaemia syndromes when ...
Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...
Posted by Michael Wonder on 27 Mar 2023
Kite's Yescarta (axicabtagene ciloleucel) first CAR T-cell therapy to receive Health Canada authorisation for use in second-line large B-cell lymphoma
23 March 2023 - Landmark ZUMA-7 study demonstrated patients on Yescarta were 2.5 times more likely to be alive at ...
Posted by Michael Wonder on 27 Mar 2023
Health Canada authorises Imbruvica (ibrutinib) in a fixed duration combination with venetoclax for adult patients with previously untreated chronic lymphocytic leukaemia
23 March 2023 - All oral, once daily, fixed duration combination regimen authorised for first-line treatment of CLL. ...